Nanobac Pharmaceuticals, Incorporated
NNBP
$0.00
$0.000.00%
OTC PK
| 12/31/2007 | 09/30/2007 | 06/30/2007 | 03/31/2007 | 12/31/2006 | |
|---|---|---|---|---|---|
| Revenue | 91.30% | -75.73% | -93.62% | -96.90% | -98.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.30% | -75.73% | -93.62% | -96.90% | -98.89% |
| Cost of Revenue | 428.57% | -58.41% | -91.59% | -90.49% | -99.13% |
| Gross Profit | -56.25% | -91.27% | -96.64% | -99.31% | -98.74% |
| SG&A Expenses | -21.45% | -40.39% | 1.53% | 544.80% | -3.07% |
| Depreciation & Amortization | -3.07% | -2.80% | -2.12% | -38.04% | -39.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.75% | -28.80% | -19.48% | 182.34% | 33.93% |
| Operating Income | 51.99% | 27.28% | 16.04% | -242.69% | -67.22% |
| Income Before Tax | 10.43% | -6.17% | 14.23% | -159.24% | -50.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.43% | -6.17% | 14.23% | -159.24% | -50.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.43% | -6.17% | 14.23% | -159.24% | -50.86% |
| EBIT | 51.99% | 27.28% | 16.04% | -242.69% | -67.22% |
| EBITDA | 56.55% | 31.95% | 18.41% | -337.36% | -99.70% |
| EPS Basic | 25.40% | 12.82% | 30.95% | -111.54% | -43.18% |
| Normalized Basic EPS | 60.47% | 12.50% | 30.77% | -148.00% | -59.26% |
| EPS Diluted | 25.40% | 12.82% | 30.95% | -111.54% | -43.18% |
| Normalized Diluted EPS | 60.47% | 12.50% | 30.77% | -148.00% | -59.26% |
| Average Basic Shares Outstanding | 21.82% | 22.08% | 24.94% | 21.93% | 4.65% |
| Average Diluted Shares Outstanding | 21.82% | 22.08% | 24.94% | 21.93% | 4.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |